Search results for "OSiS"

showing 10 items of 15931 documents

Retinal abnormalities in multiple sclerosis patients with associated chronic cerebrospinal venous insufficiency

2012

Optical coherence tomography (OCT) is a non-invasive method for the assessment of optic nerve fibers and retinal ganglion cells. This study was aimed at the assessment of retinal abnormalities in multiple sclerosis patients in the context of chronic cerebrospinal venous insufficiency using OCT of the retina and the optic nerve. We examined 239 multiple sclerosis (MS) patients, including 220 patients with associated chronic cerebrospinal venous insufficiency and 19 MS patients without venous pathology. The following OCT parameters were assessed: average ganglion cell complex thickness, global loss volume, focal loss volume and average retinal nerve fibre layer thickness. Abnormalities in the…

retinalcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyPathologygenetic structuresVenographymultiple sclerosisRetinal ganglionoptic nervemultiple sclerosis optic nerve optical coherence tomography retina venous insufficiency.Ophthalmologyvenous insufficiencymedicineOptic neuritisInternal jugular veinRetinaoptical coherence tomographymedicine.diagnostic_testbusiness.industryMultiple sclerosismedicine.diseaseeye diseasesChronic cerebrospinal venous insufficiencymedicine.anatomical_structurelcsh:RC666-701Optic nervesense organsbusinessVeins and Lymphatics
researchProduct

Inflammatory cytokines shape a changing DNA methylome in monocytes mirroring disease activity in rheumatoid arthritis

2019

Objective: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that mainly targets joints. Monocytes and macrophages are critical in RA pathogenesis and contribute to inflammatory lesions. These extremely plastic cells respond to extracellular signals which cause epigenomic changes that define their pathogenic phenotype. Here, we interrogated how DNA methylation alterations in RA monocytes are determined by extracellular signals. Methods: High-throughput DNA methylation analyses of patients with RA and controls and in vitro cytokine stimulation were used to investigate the underlying mechanisms behind DNA methylation alterations in RA as well as their relationship with clinic…

rheumatoid arthritis0301 basic medicine*DAS28Immunology*disease activityGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokineArthritis RheumatoidPathogenesisEpigenome03 medical and health sciences0302 clinical medicineRheumatologymedicineDAS28HumansImmunology and AllergyEpigenomics030203 arthritis & rheumatologyDNA methylationTumor Necrosis Factor-alphabusiness.industryMacrophagesMonocyteTNFaMethylationDNA Methylationmedicine.disease*rheumatoid arthritis030104 developmental biologymedicine.anatomical_structure*TNFaRheumatoid arthritis*DNA methylationImmunologyDNA methylationLeukocytes MononuclearCytokinesTumor necrosis factor alphaInflammation Mediatorsbusinessdisease activityBiomarkersAnnals of the Rheumatic Diseases
researchProduct

Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-α blockers: The GI…

2007

OBJECTIVE: To assess the prevalence of good clinical response and remission in rheumatoid arthritis (RA) patients with longstanding disease treated with anti-tumor necrosis factor-alpha (TNF-alpha) drugs at outpatient clinics. METHODS: Retrospective national study of 14 academic tertiary referral rheumatology medical centers. RA patients with a Disease Activity Score (DAS28) > 3.2 were defined as having active disease and could start TNF-alpha blockers. All patients received one TNF-alpha blocker plus methotrexate (10-20 mg/wk). At the third month the patients were categorized as responders or nonresponders, based on improvement of at least 0.25 of the Health Assessment Questionnaire (HAQ).…

rheumatoid arthritisAdultMaleQuality Assurance Health Carepredictors of remissionTumor Necrosis Factor blockersAntibodies Monoclonal HumanizedSeverity of Illness IndexReceptors Tumor Necrosis FactorEtanerceptArthritis RheumatoidRheumatoid arthritis; Good clinical response; Tumor Necrosis Factor blockersPredictive Value of TestsHumansRheumatoid arthritispredictors of remission; rheumatoid arthritis; tumor necrosis factor-alpha blockersAgedRetrospective StudiesGood clinical responseTumor Necrosis Factor-alphatumor necrosis factor-alpha blockersRemission InductionAdalimumabAntibodies MonoclonalMiddle AgedPrognosisInfliximabLogistic ModelsMethotrexateTreatment Outcomedisability score; good clinical response; remission; rheumatoid arthritis; tumor necrosis factor-α blockersItalyAntirheumatic AgentsImmunoglobulin GFemale
researchProduct

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side ef…

2007

Objective: To evaluate the efficacy of switching to etanercept treatment in patients with rheumatoid arthritis who already responded to infliximab, but presented side effects. Methods: Charts of 553 patients with rheumatoid arthritis were retrospectively reviewed to select patients who responded to the treatment with infliximab and switched to etanercept because of occurrence of adverse effects. Clinical data were gathered during 24 weeks of etanercept treatment and for the same period of infliximab treatment before infliximab was stopped. Disease Activity Score computed on 44 joints (DAS-44), erythrocyte sedimentation rate (ESR) 1st hour, Visual Analogue Scale (VAS) of pain, Health Assessm…

rheumatoid arthritisMaleConcise ReportArthritisGastroenterologyReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis Rheumatoidimmune system diseasesImmunology and AllergyHealth Status Indicatorsskin and connective tissue diseasesmedicine.diagnostic_testbiologyAntibodies MonoclonalMiddle AgedC-Reactive ProteinTreatment OutcomeBiologic agents; etanercept; infliximab; infusion reactionRheumatoid arthritisErythrocyte sedimentation rateAntirheumatic AgentsFemalemedicine.drugmusculoskeletal diseasesAdultmedicine.medical_specialtyVisual analogue scaleImmunologyBlood Sedimentationinfusion reactionGeneral Biochemistry Genetics and Molecular BiologyRheumatologyInternal medicinemedicineHumansAdverse effectRetrospective StudiesChi-Square Distributionbusiness.industryTumor Necrosis Factor-alphaC-reactive proteinetanercept; infliximab; rheumatoid arthritismedicine.diseaseInfliximabInfliximabSurgeryBiologic agentsstomatognathic diseasesImmunoglobulin Gbiology.proteinbusinessinfliximabetanercept
researchProduct

FRI0030 Anti-TNF-α Antibody Targeted To Inflamed Synovial Tissue for The Treatment of Rheumatoid Arthritis

2016

Background TNF-α neutralizing molecules represent one of the most efficient therapeutic approaches to control inflammation in rheumatoid arthritis (RA). The widespread distribution in the body induces the inhibition of TNF-α in all the tissues, requesting the use of high dose of this expensive drug. Another problem that has not yet been solved in the management of RA patients is how to reduce and possibly avoid the side effects, particularly the increased risk of common and opportunistic infections, which may be associated with long-term administration of these therapeutic drugs. Objectives The aim of the present investigation was to show that a recombinant protein obtained by fusing a syno…

rheumatoid arthritisPathologymedicine.medical_specialtyImmunologyArthritisInflammationImmunofluorescenceGeneral Biochemistry Genetics and Molecular BiologyRheumatologyIn vivoAdalimumabmedicineImmunology and AllergyNeutralizing antibodyantigen induced arthritismedicine.diagnostic_testbiologybusiness.industrytarget therapyantigen induced arthritirheumatoid arthritimedicine.diseaseRheumatoid arthritisImmunologyrheumatoid arthritis; antigen induced arthritis; target therapy; immunotherapybiology.proteinTumor necrosis factor alphaimmunotherapymedicine.symptombusinessmedicine.drug
researchProduct

Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders.

2021

The past decades have yielded major therapeutic advances in many autoimmune conditions – such as multiple sclerosis (MS) – and thus ushered in a new era of more targeted and increasingly potent immunotherapies. Yet this growing arsenal of therapeutic immune interventions has also rendered therapy much more challenging for the attending physician, especially when treating patients with more than one autoimmune condition. Importantly, some therapeutic strategies are either approved for several autoimmune disorders or may be repurposed for other conditions, therefore opening new curative possibilities in related fields. In this article, we especially focus on frequent and therapeutically rele…

rheumatoid arthritismedicine.medical_specialtymedicine.medical_treatmentPsychological interventionReviewmultiple sclerosisInflammatory bowel diseaseinflammatory bowel diseasePsoriasismedicineRC346-429Intensive care medicinePharmacologybusiness.industryMultiple sclerosisInflammatory Bowel DiseasesImmunotherapypsoriasismedicine.diseaseNeurologyRheumatoid arthritisNeurology. Diseases of the nervous systemNeurology (clinical)immunotherapyAutoimmune conditionbusinessTherapeutic advances in neurological disorders
researchProduct

Rho GTPases Are Involved in the Regulation of NF-κB by Genotoxic Stress

2001

A common cellular response to genotoxic agents and inflammatory cytokines is the activation of NF-kappaB. Here, we addressed the question of whether small GTPases of the Rho family are involved in the stimulation of NF-kappaB signaling by genotoxic agents or TNFalpha in HeLa cells. Inhibition of isoprenylation of Rho proteins by use of the HMG-CoA reductase inhibitor lovastatin attenuated UV-, doxorubicin-, and TNFalpha-induced degradation of IkappaBalpha as well as drug-stimulated DNA binding activity of NF-kappaB. Furthermore, NF-kappaB-regulated gene expression stimulated by either UV irradiation or treatment with TNFalpha was abrogated by lovastatin pretreatment. This indicates that iso…

rho GTP-Binding ProteinsBacterial ToxinsClostridium difficile toxin BGenotoxic StressGTPaseBiologyProinflammatory cytokinechemistry.chemical_compoundBacterial ProteinsNF-KappaB Inhibitor alphamedicineHumansLovastatinTumor Necrosis Factor-alphaNF-kappa BNF-kappa B p50 SubunitNF-κBCell BiologyCell biologyDNA-Binding ProteinsIκBαchemistryDoxorubicinI-kappa B ProteinsTumor necrosis factor alphaLovastatinHeLa CellsSignal Transductionmedicine.drugExperimental Cell Research
researchProduct

A novel microtubule de-stabilizing complementarity-determining region C36L1 peptide displays antitumor activity against melanoma in vitro and in vivo

2015

AbstractShort peptide sequences from complementarity-determining regions (CDRs) of different immunoglobulins may exert anti-infective, immunomodulatory and antitumor activities regardless of the specificity of the original monoclonal antibody (mAb). In this sense, they resemble early molecules of innate immunity. C36L1 was identified as a bioactive light-chain CDR1 peptide by screening 19 conserved CDR sequences targeting murine B16F10-Nex2 melanoma. The 17-amino acid peptide is readily taken up by melanoma cells and acts on microtubules causing depolymerization, stress of the endoplasmic reticulum and intrinsic apoptosis. At low concentrations, C36L1 inhibited migration, invasion and proli…

rho GTP-Binding ProteinsMelanoma ExperimentalAntineoplastic AgentsApoptosisPeptideComplementarity determining regionBiologyEndoplasmic ReticulumMicrotubulesArticleMicePhosphatidylinositol 3-KinasesCell MovementTubulinCell Line TumormedicineAnimalsNeoplasm MetastasisMelanomaPI3K/AKT/mTOR pathwayCell Proliferationchemistry.chemical_classificationMultidisciplinaryInnate immune systemCell growthMelanomaIntrinsic apoptosisPTEN Phosphohydrolasemedicine.diseaseComplementarity Determining RegionsMolecular biologyMitochondriaDisease Models AnimalchemistryCell cultureCancer researchProtein MultimerizationPeptidesProto-Oncogene Proteins c-aktSignal TransductionScientific Reports
researchProduct

Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion.

2003

E-selectin mediated cell-cell adhesion plays an important role in inflammatory processes and extravasation of tumor cells. Tumor necrosis factor-alpha (TNF-alpha) induces E-selectin gene and protein expression in primary human endothelial cells (HUVEC) and in an endothelial cell line (EA.hy-926). As shown by ELISA and FACS analyses, HMG-CoA reductase inhibitors (e.g., lovastatin) impair the TNF-alpha stimulated increase in E-selectin protein expression. Similar results were obtained for E-selectin mRNA expression and promoter activity, indicating that the effect of lovastatin is based on inhibition of gene expression. The effective inhibitory concentration of lovastatin was in a physiologic…

rho GTP-Binding ProteinsRHOATranscription GeneticRHOBAntineoplastic AgentsBiochemistryCell MovementCell Line TumorNeoplasmsGene expressionE-selectinGeneticsmedicineCell AdhesionHumansLovastatinCell adhesionMolecular BiologyCells CulturedbiologyTumor Necrosis Factor-alphaCell biologybiology.proteinCancer researchTumor necrosis factor alphaLovastatinEndothelium VascularSignal transductionE-SelectinBiotechnologymedicine.drugSignal TransductionFASEB journal : official publication of the Federation of American Societies for Experimental Biology
researchProduct

Detection of natural killer T cells in mice infected with Rickettsia conorii.

2013

Little information is available regarding the role of natural killer T (NKT) cells during the early stage of Rickettsia conorii infection. Herein, C3H/HeN mice were infected with the Malish 7 strain of R. conorii. Splenocytes from these mice were analysed in the early stage of the infection by flow cytometry and compared with uninfected controls. Our results showed an increase in NKT cells in infected mice. Additionally, NKT interleukin (IL)-17(+) cells increased three days after infection, together with a concurrent decrease in the relative amount of NKT interferon (IFN)-γ(+) cells. We also confirmed a higher amount of NK IFN-γ(+) cells in infected mice. Taken together, our data showed tha…

rickettsiosis; interleukin 17; interferon-γchemical and pharmacologic phenomenaSpleenrickettsiosisBiologyBoutonneuse FeverFlow cytometryMiceInterferonmedicineAnimalsCells CulturedImmunity CellularMice Inbred C3HGeneral VeterinaryGeneral Immunology and Microbiologymedicine.diagnostic_testInterleukinGeneral Medicinemedicine.diseaseNatural killer T cellbiology.organism_classificationInterferon-γ; interleukin 17; rickettsiosisVirologyRickettsia conoriiRickettsiosismedicine.anatomical_structureImmunologyNatural Killer T-CellsInterferon-γInterleukin 17Rickettsia conoriiinterleukin 17Spleenmedicine.drugTransboundary and emerging diseases
researchProduct